Industry
Biotechnology
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Loading...
Open
1.80
Mkt cap
64M
Volume
17K
High
1.83
P/E Ratio
-6.73
52-wk high
3.35
Low
1.75
Div yield
N/A
52-wk low
0.52
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 11:58 am
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 8:39 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 8:18 pm
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 12:54 pm
Portfolio Pulse from Benzinga Newsdesk
March 20, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
March 08, 2024 | 9:17 pm
Portfolio Pulse from Benzinga Newsdesk
March 04, 2024 | 1:47 pm
Portfolio Pulse from Benzinga Newsdesk
January 03, 2024 | 1:49 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.